S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 25 of 25

Issue Date	Title / Author(s) / Citation	File
2008-10	Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study Rothenberg, M. L.; Cox, J. V.; Butts, C.; Navarro, M.; Bang, Y. -J.; Goel, R.; Gollins, S.; Siu, L. L.; Laguerre, S.; Cunningham, D. Annals of Oncology, Vol.19 No.10, pp.1720-1726	DOI
2011-04	Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study Lim, Robert; Sun, Yan; Im, Seock-Ah; Hsieh, Ruey-Kuen; Yau, Tsz Kok; Bonaventura, Anthony; Cheirsilpa, Arkom; Esser, Regina; Mueser, Matthias; Advani, Suresh World Journal of Gastroenterology, Vol.17 No.14, pp.1879-1888	DOI
2012-08	Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy Kim, N.; Park, C.; Park, D. J.; Kim, H. -H.; Kim, S.; Kim, Y. J.; Kim, J. H.; Lee, J. S.; Bang, Y. -J.; Khwarg, S. I.; Choung, H.; Lee, M. J.; Lee, K. -W. Annals of Oncology, Vol.23 No.8, pp.2065-2071	DOI
2012-12	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial de Gramont, Aimery; Van Cutsem, Eric; Schmoll, Hans-Joachim; Tabernero, Josep; Clarke, Stephen; Moore, Malcolm J.; Cunningham, David; Cartwright, Thomas H.; Hecht, J. Randolph; Rivera, Fernando; Im, Seock-Ah; Bodoky, Gyoergy; Salazar, Ramon; Maindrault-Goebel, Frederique; Shacham-Shmueli, Einat; Bajetta, Emilio; Makrutzki, Martina; Shang, Aijing; Andre, Thierry; Hoff, Paulo M. The Lancet Oncology, Vol.13 No.12, pp.1225-1233	DOI
2013-10	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer Cortes, J.; Baselga, J.; Im, Y. -H.; Im, S. -A.; Pivot, X.; Ross, G.; Clark, E.; Knott, A.; Swain, S. M. Annals of Oncology, Vol.24 No.10, pp.2630-2635	DOI
2014-08	Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial Kim, Sung-Bae; Yoo, Changhoon; Ro, Jungsil; Im, Seock-Ah; Im, Young-Hyuck; Kim, Jee Hyun; Ahn, Jin-Hee; Jung, Kyung Hae; Song, Hong Suk; Kang, Seok Yun; Park, Hee Sook; Chung, Hyun-Cheol Investigational New Drugs, Vol.32 No.4, pp.753-761	DOI
2014-09	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William Cancer Discovery, Vol.4 No.9, pp.1046-1061	DOI
2015-04	The impact of molecularly targeted treatment on direct medical costs in patients with advanced non-small cell lung cancer Lee, June-Koo; Kim, Dong-Wan; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Young-Joo; Heo, Dae Seog Cancer Research and Treatment, Vol.47 No.2, pp.182-188	view file DOI
2016-02	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee, Ji Yun; Xu Qing; Wei Xiumin; Bai Yali; Chi, Sangah; Bak, So Hyeon; Lee, Ho Yun; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Hye Ryun; Min, Young Joo; Jung, Sin-Ho; Park, Keunchil; Mao Mao; Ahn, Myung-Ju Oncotarget, Vol.7 No.6, pp.6984-6993	view file DOI
2016-03	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer Park, Sehhoon; Park, Seongyeol; Lee, Se-Hoon; Suh, Beomseok; Ock, Chan-Young; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog Cancer Biomarkers, Vol.16 No.3, pp.425-433	DOI
2016-11	Palbociclib and Letrozole in Advanced Breast Cancer Finn, Richard S.; Martin, Miguel; Rugo, Hope S.; Jones, Stephen; Im, Seock-Ah; Gelmon, Karen; Harbeck, Nadia; Lipatov, Oleg N.; Walshe, Janice M.; Moulder, Stacy; Gauthier, Eric; Lu, Dongrui R.; Randolph, Sophia; Dieras, Veronique; Slamon, Dennis J. New England Journal of Medicine, Vol.375 No.20, pp.1925-1936	DOI
2017-01	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-O13/LOGiC Trial of Lapatinib Press, Michael F.; Ellis, Catherine E.; Gagnon, Robert C.; Grob, Tobias J.; Buyse, Marc; Villalobos, Ivonne; Liang, Zhiyong; Wu, Shafei; Bang, Yung-Jue; Qin, Shu-Kui; Chung, Hyun Cheol; Xu, Jianming; Park, Joon Oh; Jeziorski, Krzysztof; Afenjar, Karen; Ma, Yanling; Estrada, Monica C.; Robinson, Douglas M.; Scherer, Stefan J.; Sauter, Guido; Hecht, J. Randolph; Slamon, Dennis J. Molecular Cancer Therapeutics, Vol.16 No.1, pp.228-238	DOI
2017-02	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Paz-Ares, L.; Tan, E. -H.; O'Byrne, K.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J. C. -H.; Mok, T.; Lee, K. H.; Lu, S.; Shi, Y.; Lee, D. H.; Laskin, J.; Kim, D. -W.; Laurie, S. A.; Kolbeck, K.; Fan, J.; Dodd, N.; Marten, A.; Park, K. Annals of Oncology, Vol.28 No.2, pp.270-277	DOI
2017-04	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component Yang, James Chih-Hsin; Ahn, Myung-Ju; Kim, Dong-Wan; Ramalingam, Suresh S.; Sequist, Lecia V.; Su, Wu-Chou; Kim, Sang-We; Kim, Joo-Hang; Planchard, David; Felip, Enriqueta; Blackhall, Fiona; Haggstrom, Daniel; Yoh, Kiyotaka; Novello, Silvia; Gold, Kathryn; Hirashima, Tomonori; Lin, Chia-Chi; Mann, Helen; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A. Journal of Clinical Oncology, Vol.35 No.12, pp.1288-1296	DOI
2018-03	Phase III, Randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE Johnston, Stephen R. D.; Hegg, Roberto; Im, Seock-Ah; Park, In Hae; Burdaeva, Olga; Kurteva, Galina; Press, Michael F.; Tjulandin, Sergei; Iwata, Hiroji; Simon, Sergio D.; Kenny, Sarah; Sarp, Severine; Izquierdo, Miguel A.; Williams, Lisa S.; Gradishar, William J. Journal of Clinical Oncology, Vol.36 No.8, pp.741-748	DOI
2018-03	Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases Turner, N. C.; Finn, R. S.; Martin, M.; Im, S. -A; DeMichele, A.; Ettl, J.; Dieras, V.; Moulder, S.; Lipatov, O.; Colleoni, M.; Cristofanilli, M.; Lu, D. R.; Mori, A.; Giorgetti, C.; Iyer, S.; Bartlett, C. Huang; Gelmon, K. A. Annals of Oncology, Vol.29 No.3, pp.669-680	DOI
2018-05	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells Min, Ahrum; Kim, Jung Eun; Kim, Yu-Jin; Lim, Jee Min; Kim, Seongyeong; Kim, Jin Won; Lee, Kyung-Hun; Kim, Tae-Yong; Oh, Do-Youn; Bang, Yung-Jue; Im, Seock-Ah Cancer Letters, Vol.430, pp.123-132	DOI
2018-07	Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors Kim, Tae Min; Lee, Keun-Wook; Oh, Do-Youn; Lee, Jong-Seok; Im, Seock-Ah; Kim, Dong-Wan; Han, Sae-Won; Kim, Yu Jung; Kim, Tae-You; Kim, Jee Hyun; Han, Hyesun; Kim, Woo Ho; Bang, Yung-Jue Cancer Research and Treatment, Vol.50 No.3, pp.835-842	DOI
2019-07	Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 Remon, Jordi; Ahn, Myung-Ju; Girard, Nicolas; Johnson, Melissa; Kim, Dong-Wan; Lopes, Gilberto; Pillai, Rathi N.; Solomon, Benjamin; Villacampa, Guillermo; Zhou, Qing Journal of Thoracic Oncology, Vol.14 No.7, pp.1134-1155	DOI
2019-09	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial Kim, Dong-Wan; Lee, Dae Ho; Han, Ji-Youn; Lee, Jongseok; Cho, Byoung Chul; Kang, Jin Hyoung; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Jin-Soo; Min, Young Joo; Cho, Jae Yong; An, Ho Jung; Kim, Hoon-Gu; Lee, Kyung Hee; Kim, Bong-Seog; Jang, In-Jin; Yoon, Seonghae; Han, OakPil; Noh, Young Su; Hong, Ka Young; Park, Keunchil Lung Cancer, Vol.135, pp.66-72	DOI
2020-01	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial Lee, Gyeong-Won; Go, Se-Il; Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; An, Ho Jung; Jang, Joung Soon; Kim, Bong-Seog; Hahn, Seokyung; Heo, Dae Seog Thoracic Cancer, Vol.11 No.1, pp.62-71	view file DOI
2020-01	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer Finn, Richard S.; Liu, Yuan; Zhu, Zhou; Martin, Miguel; Rugo, Hope S.; Dieras, Veronique; Im, Seock-Ah; Gelmon, Karen A.; Harbeck, Nadia; Lu, Dongrui R.; Gauthier, Eric; Bartlett, Cynthia Huang; Slamon, Dennis J. Clinical Cancer Research, Vol.26 No.1, pp.110-121	DOI
2021-01	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE Johnston, Stephen R. D.; Hegg, Roberto; Im, Seock-Ah; Park, In Hae; Burdaeva, Olga; Kurteva, Galina; Press, Michael F.; Tjulandin, Sergei; Iwata, Hiroji; Simon, Sergio D.; Kenny, Sarah; Sarp, Severine; Izquierdo, Miguel A.; Williams, Lisa S.; Gradishar, William J. Journal of Clinical Oncology, Vol.39 No.1, pp.79-89	DOI
2021-09	Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer Cho, Byoung Chul; Yoh, Kiyotaka; Perets, Ruth; Nagrial, Adnan; Spigel, David R.; Gutierrez, Martin; Kim, Dong-Wan; Kotasek, Dusan; Rasco, Drew; Niu, Jiaxin; Satouchi, Miyako; Ahn, Myung-Ju; Lee, Dae Ho; Maurice-Dror, Corinne; Siddiqi, Shabana; Ren, Yixin; Altura, Rachel A.; Bar, Jair Lung Cancer, Vol.159, pp.162-170	DOI
2023-10	Amivantamab plus lazertinib in osimertinib-relapsed <i>EGFR</i>-mutant advanced non-small cell lung cancer: a phase 1 trial Cho, Byoung Chul; Kim, Dong-Wan; Spira, Alexander I.; Gomez, Jorge E.; Haura, Eric B.; Kim, Sang-We; Sanborn, Rachel E.; Cho, Eun Kyung; Lee, Ki Hyeong; Minchom, Anna; Lee, Jong-Seok; Han, Ji-Youn; Nagasaka, Misako; Sabari, Joshua K.; Ou, Sai-Hong Ignatius; Lorenzini, Patricia; Bauml, Joshua M.; Curtin, Joshua C.; Roshak, Amy; Gao, Grace; Xie, John; Thayu, Meena; Knoblauch, Roland E.; Park, Keunchil Nature Medicine, Vol.29 No.10, pp.2577-2585	DOI